The neuronal ceroid lipofuscinoses: Clinical features and molecular basis of disease

Lysosomal Storage Disorders

Volumn , Issue , 2007, Pages 371-388

  Davidson, Beverly L ^a   Cabrera Salazar, Mario A ^b   Pearce, David A ^c  

^a UNIVERSITY OF IOWA   (United States)

^b GENZYME CORPORATION   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66349115608     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-70909-3_23     Document Type: Chapter

References (86)

1. Aberg LE, Backman M, Kirveskari E, Santavuori P, (2000). Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia 41(10):1296-1302.
2. Bellizzi JJ 3rd, Widom J, Kemp C, Lu JY, Das AK, Hofmann SL, Clardy J, (2000). The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 97:4573-4578.
3. Bolivar VJ, Scott Ganus J, Messer A, (2002). The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Res 937:74-82.
4. Boustany RM, Alroy J, Kolodny EH, (1988). Clinical classification of neuronal ceroid-lipofuscinosis subtypes. Am J Med Genet Suppl. 5:47-58.
5. Bronson RT, Donahue LR, Johnson KR, Tanner A, Lane PW, Faust JR, (1998). Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. Am J Med Genet 77:289-297.
6. Broom MF, Zhou C, (2001). Fine mapping of ovine ceroid lipofuscinosis confirms orthology with CLN6. Eur J Paediatr Neurol 5 Suppl A: 33-35.
7. Calero G, Gupta P, Nonato MC, Tandel S, Biehl ER, Hofmann SL, Clardy J, (2003). The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2. J Biol Chem 278:37957-37964.
8. Chattopadhyay S and Pearce DA, (2000). Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN 1, CLN2, and CLN3: functional implications for CLN3. Mol Genet Metab 71:207-211.
9. Cotman SL, Vrbanac V, Lebel LA, Lee RL, Johnson KA, Donahue LR, Teed AM, Antonellis K, Bronson RT, Lerner TJ, MacDonald ME, (2002). Cln3 (Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum Mol Genet 11:2709-2721.
10. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt M, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H, (2004). Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 15:1131-1154.
11. Das AK, Becerra CH, Yi W, Lu JY, Siakotos AN, Wisniewski KE, Hofmann SL, (1998). Molecular genetics of palmitoyl-protein thioesterase deficiency in the U. S. J Clin Invest 102(2):361-370.
12. Das AK, Lu JY, Hoffman SL, (2001). Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipo-fuscinosis. Hum Mol Genet 10:1431-1439.
13. Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koeberl DD, Amalfitano A, Boustany RM, (2002). Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 51:448-466.
14. Ezaki J, and Kominami E, 2004. The intracellular location and function of proteins of neuronal ceroid lipofuscinoses. Brain Pathol 14:77-85.
15. Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, Mineki R, Murayama K, Uchiyama Y, Ueno T, Kominami E, (2003). Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J Neurochem 87:1296-1308.
16. Ezaki J, Tanida I, Kanehagi N, Kominami E, (1999). A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J Neurochem 72:2573-2582.
17. Ezaki J, Wolfe LS, Kominami E, (1997). Decreased lysosomal subunit c-degrading activity in fibroblasts from patients with late infantile neuronal ceroid lipofuscinosis. Neuropediatrics 28:53-55.
18. Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME, (2002). Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 70:324-335.
19. Golabek AA, Kida E, Walus M, Wujek P, Mehta P, Wisniewski KE, (2000). CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol Genet Metab 70:203-213.
20. Golabek AA, Kida E, Walus M, Wujek P, Mehta P, Wisniewski KE, (2003) Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. J Biol Chem 278:7135-7145.
21. Golabek AA, Walus M, Wisniewski KE, Kida E, (2005). Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo. J Biol Chem 280:7550-7561.
22. Griffey M, Bible E, Vogler C, Levy B, Gupta P, Cooper J, Sands MS, (2004). Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of Infantile Neuronal Ceroid Lipofus-cinosis (INCL). Neurobiol Dis 16:360-369.
23. Griffey MA, Wozniak D, Wong M, Bible E, Johnson K, Rothman SM, Wentz AE, Cooper JD, Sands MS, (2006). CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther. 13:538-547.
24. Gupta P, Soyombo AA, Atashband A, Wisniewski KE, Shelton JM, Richardson JA, Hammer RE, Hofmann SL, (2001). Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. PNAS, USA 98:13566-13571.
25. Haskell RE, Carr CJ, Pearce DA, Bennett MJ, Davidson BL (2000). Batten Disease: Evaluation of CLN3 mutations on protein trafficking and function. Hum Mol Genet 9:735-744.
26. Haskell RE, Hughes SM, Chiorini JA, Alisky JM, Davidson BL, (2003). Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP I to the mouse central nervous system. Gene Ther 10:34-42.
27. Heine C, Koch B, Storch S, Kohlschutter A, Palmer DN, Braulke T, (2004). Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem 279:22347-22352.
28. Heinonen O, Salonen T, Jalanko A, Peltonen L, Copp A, (2000). CLN-1 and CLN-5, genes for infantile and variant late infantile neuronal ceroid lipofuscinoses, are expressed in the embryonic human brain. J Comp Neurol 426:406-412.
29. Hellsten E, Vesa J, Olkkonen VM, Jalanko A, Peltonen L, (1996). Human palmitoyl protein thioesterase: Evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. EMBO J 15:5240-5245.
30. Holmberg V, Jalanko A, Isosomppi J, Fabritius AL, Peltonen L, Kopra O, (2004). The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain. Neurobiol Dis 16:29-40.
31. Holmberg V, Lauronen L, Autti T, Santavuori P, Savukoski M, Uvebrant P, Hofman I, Peltonen L, Jarvela I, (2000). Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). Neurology 55:579-581.
32. Holopainen JM, Saarikoski J, Kinnunen PK, Jarvela I, (2001). Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem 268:5851-5856.
33. Isosomppi J, Heinonen O, Hiltunen JO, Greene ND, Vesa J, Uusitalo A, Mitchison HM, Saarma M, Jalanko A, Peltonen L, (1999). Developmental expression of palmitoyl protein thioesterase in normal mice. Brain Res Dev Brain Res 118:1-11.
34. Isosomppi J, Vesa J, Jalanko A, Peltonen L, (2002). Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein. Hum Mol Genet 11:885-891.
35. Jalanko A, Vesa J, Manninen T, von Schantz C, Minye H, Fabritius AL, Salonen T, Rapola J, Gentile M, Kopra O, Peltonen L, (2005). Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of inter-neurons. Neurobiol Dis 18:226-241.
36. Jarvela I, Lehtovirta M, Tikkanen R, Kyttala A, Jalanko A, (1999). Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 8(6):1091-1098.
37. Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage Fh, Peterson DA (2002). Targeted retrograde gene delivery for neuronal protection. Mol Ther 5:50-56.
38. Katz ML, Shibuya H, Liu PC, Kaur S, Gao CL, Johnson GS, (1999). A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). J Neurosci Res 57:551-556.
39. Kida E, Golabek AA, Walus M, Wujek P, Kaczmarski W, Wisniewski KE, (2001). Distribution of tripeptidyl peptidase I in human tissues under normal and pathological conditions. J Neuropathol Exp Neurol 60:280-292.
40. Kim M, Mao Q, Davidson BL, Wiemer DF, (2003). Tripeptide probes for tripeptidyl protease I production via gene transfer. J Med Chem 46:1603-1608.
41. Kopan S, Sivasubramaniam U, Warburton MJ, (2004). The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun 319:58-65.
42. Kopra O, Vesa J, von Schantz C, Manninen T, Minye H, Fabritius AL, Rapola J, van Diggelen OP, Saarela J, Jalanko A, Peltonen L, (2004). A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging. Hum Mol Genet 13:2893-2906.
43. Lake BD, Steward CG, Oakhill A, Wilson J, Perham TG, (1997). Bone marrow transplantation in late infantile Batten disease and juvenile Batten disease. Neuropediatrics. 28:80-81.
44. Lerner TJ, Boustany RM, Anderson JW, D'Arigo KL, Schlumpf K, Bucker AJ, Gusella JF, Haines JL, Kremmidiotis G, Lensink IL, Sutherland GR, Callen DF, Taschner PE, De Vos N, Van Ommen GJ, Breuning MH, Doggett NA, Meincke LJ, Liu Z, Goodwin LA, Tesmer JG, Mitchson HM, O'Rawe AM, Munroe PB (1995). Isolation of a novel gene underlying Batten disease, CLN3. Cell 82:949-957.
45. Lin NL, Lobel P (2001) a. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofus. Biochem J 357:49-55.
46. Lin NL, Sohart I, Lackland H, Lobel P (2001) b. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. J Biol Chem 276:2249-2255.
47. Liu CG, Sleat DE, Donnelly RJ, Lobel P (1998). Structural organization and sequence of CLN2, the defective gene in classical late infantile neuronal ceroid lipofuscinosis. Genomics 50:206-212.
48. Lonka L, Kyttala A, Ranta S, Jalanko A, Lehesjoki AE (2000). The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. Hum Mol Genet 9:1691-1697.
49. Luiro K, Kopra O, Lehtovirta M, Jalanko A (2001). CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: New clues to Batten disease. Hum Mol Genet 10:2123-2131.
50. Mao Q, Foster BJ, Xia H, Davidson BL, (2003a). Membrane topology of CLN3, the protein underlying Batten disease. FEBS Lett 541:40-46.
51. Mao Q, Xia H, Davidson BL, (2003b). Intracellular trafficking of CLN2, the protein underlying the childhood neurodegenerative disease, Batten disease. FEBS Lett 555:351-357.
52. Margraf LR, Boriack RL, Routheut AA, Cuppen I, Alhilali L, Bennett CJ, Bennett MJ, (1999). Tissue expression and subcellular localion of CLN3, the Batten disease protein. Mol Gen Metab 66:283-289.
53. Marshall FJ, De Blieck EA, Mink JW, Dure L, Adams H, Messin, S, Rothberg PG, Levy E, McDonough T, DeYoung J, Wang M, Ramirez-Montealegre D, Kwon JM, Pearce DA, (2005) A clinical rating scale for Batten disease: Reliable and relevant for clinical trials. Neurology 65(2):275-279.
54. Mitchison HM, Bernard DJ, Greene ND, Cooper JD, Junaid MA, Pullarkat RK, de Vos N, Breuning MH, Owens JW, Mobley WC, Gardiner RM, Lake BD, Taschner PE, Nussbaum RL (1999). Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium (corrected). Neurobiol Dis 6:321-334.
55. Mitchison HM, Lim MJ, Cooper JD, (2004). Selectivity and types of cell death in the neuronal ceroid lipofuscinoses. Brain Pathol 14:86-96.
56. Mole SA, Michaux G, Godlin S, Wheeler RB, Sharp JD, Cutler DF, (2004). CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res 298:399-406.
57. Mole SE (2004). The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol 14:70-76.
58. Padilla-Lopez S, Pearce DA, (2006). Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity in order to regulate pH imbalance in the vacuole. J Biol Chem. 281:10273-10280
59. Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, Sondhi D, Hackett NR, Kaminsky SM, Mao Q, Shihabuddin LS, Cheng SH, Sleat DE, Stewart GR, Davidson BL, Lobel P, Crystal RG, (2006). Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci. 26:1334-1342.
60. Pearce DA, Ferea T, Nosel SA, Das B, Sherman F (1999). Action of Btn1p, the yeast ortholog of the human Batten disease gene. Nat Genet 22:55-58.
61. Persaud-Sawin DA, Vandongen A, Boustany RM, (2002). Motifs within the CLN3 protein: Modulation of cell growth rates and apoptosis. Hum Mol Genet 11:2129-2142.
62. Pontikis CC, Cella CV, Parihar N, Lim MJ, Chakrabarti S, Mitchison HM, Mobley WC, Rezaie P, Pearce DA, Cooper JD, (2004). Late onset neurodegeneration in the Cln3-/-mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res 1023:231-242.
63. Puranam KL, Guo WX, Qian WH, Nikbakht K, Boustany RM (1999). CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol Gen Metab 66:294-308.
64. Ranta S, Topcu M, Tegelberg S, Tan H, Ustubutun A, Saatci I, Dufke A, Enders H, Pohl K, Alembik Y, Mitchell WA, Mole SE, Lehesjoki AE, (2004). Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat 23:300-305.
65. Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole S, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, Lehesjoki AE, (1999). The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat Genet 23:233-236.
66. Salonen T, Heinonen-Kopra O, Vesa J, Jalanko A, (2001). Neuronal trafficking of palmi-toyl protein thioesterase provides an excellent model to study the effects of different mutations which cause infantile neuronal ceroid lipofuscinocis. Mol Cell Neurosci 18:131-140.
67. Santavuori P, Rapola J, Nuutila A, Raininko R, Lappi M, Launes J, Herva R, Sainio K, (1991). The spectrum of Jansky-Bielschowsky disease. Neuropediatrics 22:92-96.
68. Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L, (1998). CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet 19:286-288.
69. Shahwan A, Farrell M, Delanty N, (2005). Progressive myoclonic epilepsies: A review of genetic and therapeutic aspects. Lancet Neurol. 4:239-248.
70. Sinha S, Satishchandra P, Santosh V, Gayatri N, Shankar SK (2004). Neuronal ceroid lipofuscinosis: a clinicopathological study. Seizure 13:235-240.
71. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P, (1997). Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 277:1802-1805.
72. Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower-Brooks S, Pullarkat RK, Palmer DN, Lerner TJ, Boustany RM, Uldall P, Siakotos AN, Donnelly RJ, Lobel P, (1999). Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet 64:1511-1523.
73. Sleat DE, Wiseman JA, El-Banna M, Kim KH, Mao Q, Price S, Macauley SL, Sidman RL, Shen MM, Zhao Q, Passini MA, Davidson BL, Stewart GR, Lobel P, (2004). A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci 24:9117-9126.
74. Sohar I, Sleat DE, Jadot M, Lobel P, (1999). Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J Neurochem. 73:700-711.
75. Suopanki J, Tynela J, Baumann M, Haltia M, (1999). Palmitoyl-protein thioesterase, an enzyme implicated in neurodegeneration, is localized in neurons and is develop-mentally regulated in rat brain. Neurosci Lett 265:53-56.
76. Tammen I, Cook RW, Nicholas FW, Raadsma HW, (2001). Neuronal ceroid lipofus-cinosis in Australian Merino sheep: a new animal model. Eur J Paediatr Neurol 5 Suppl A: 37-41.
77. Tian Y, Sohar I, Taylor JW, Lobel P, (2006). Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates. J Biol Chem. 281:6559-6572.
78. Tomkinson B, (1999). Tripeptidyl peptidases: enzymes that count. Trends Biochem Sci 24:355-359.
79. Tyynela J, Palmer DN, Baumann M, Haltia M Storage of saposins A and D in infantile neuronal ceroid-lipofuscinosis. FEBS Lett. (1993) 330:8-12.
80. Vanhanen SL, Puranen J, Autti T, Raininko R, Liewendahl K, Nikkinen P, Santavuori P, Suominen P, Vuori K, Hakkinen AM, (2004). Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics 35:27-35.
81. Verkruyse LA and Hoffman SL, (1996). Lysosomal targeting of palmitoyl-protein thioesterase. J Biol Chem 271:15831-15836.
82. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L, (1995). Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376:584-587.
83. Walus M, Kida E, Wisniewski KE, Golabek AA, (2005). Ser 475, Glu272, Asp 276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I. FEBS Lett 579:1383-1388.
84. Wheeler RB, Sharp JD, Schultz RA, Joslin JM, Williams RE, Mole SE, (2002). The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet 70:537-542.
85. Wisniewski KE, Zhong N, Philippart M, (2001). Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology. 57:576-581.
86. Wujek P, Kida E, Walus M, Wisniewski KE, Golabek AA, (2004). N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I. J Biol Chem 279:12827-12839.